``It's one of the most exciting developments in the treatment of arthritis in 25 years because we potentially will be able to treat people for their pain and inflammation without them suffering the side effects,'' says Rubin.
``This is the first time we have a drug reasonably well-tolerated by most people and effective for a problem that has been resistant to most treatments''.
Vioxx has an indication for treatment of acute pain; Celebrex does not _ it has been approved for the treatment of rheumatoid arthritis and osteoarthritis.
Even before the NIH study is off the drawing boards, leading US arthritis specialists are recommending glucosamine to their patients _ not as a cure, but as something that reduces pain in some people and may (or may not) retard the progress of the disease, depending on whether the European study results can be confirmed.
On the scientific side, leading researchers paint an expansive picture of the future of osteoarthritis treatment.
``We found the severity of the arthritis process was less in those given the treatment,'' and the combination of compounds worked best, said Dr. Robert R. Karpman, one of the researchers who oversaw the study in Phoenix, which is due to be published next month.
The fact that cartilage does not have blood vessels, and gets its only nutrition by seepage through the surrounding membrane, probably makes it easier for substances like glucosamine and chondroitin to work their way there, said Dr. Lou Lippiello, director of laboratory research at Nutramax Laboratories,
